Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma

Pathology Research and Practice

Volumn 206, Issue 5, 2010, Pages 305-309

  Mohammad Tavangar, Seyed ^a   Shojaee, Ali ^a   Moradi Tabriz, Hedieh ^b   Haghpanah, Vahid ^c   Larijani, Bagher ^c   Heshmat, Ramin ^c   Lashkari, Anahita ^c   Azimi, Sima ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C erbB 2; C kit; Immunohistochemistry; Ki67; Pheochromocytoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; STEM CELL FACTOR;

ADOLESCENT; ADRENAL CANCER; ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CHILD; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; SCHOOL CHILD; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77952553938     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.01.007     Document Type: Article

References (24)

1. Beard C.M., Sheps S.G., Kurtland L.T. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin. Proc. 1983, 58:802-804.
2. Castilla-Guerra L., Moreno A.M., Fernandez-Moreno M.C. Expression and prognostic value of c-erbB-2 oncogene product in human pheochromocytomas. Histopathology 1997, 31:144-149.
3. Medeiros L.J., Wolf B.C., Balogh K. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum. Pathol. 1985, 16:580-589.
4. van der Harst E., Bruining H.A., Bonjer H.J. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?. J. Pathol. 2000, 191:175-180.
5. Gupta D., Shidham V., Holden J. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-Cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl. Immunohistochem. Mol. Morphol. 2000, 8:267-274.
6. Ohji H., Sasagawa I., Iciyanagi O. Tumour angiogenesis and Ki-67 expression in Phaeochromocytoma. BJU Int. 2001, 87:381-385.
7. Saeger W., Fassnacht M., Reincke M. Expression of HER-2/neu receptor protein in adrenal tumors. Pathol. Res. Pract. 2002, 198:445-448.
8. Paes de Lima A., Arrosi V., Garcia A. Pheochromocytoma: histopathologic, immunohistochemical, proliferation and ploidy analysis. Rev. Argent Endocrinol. Metab. 1999, 36:140-152.
9. Brown H.M., Komorowski R.A., Wilson S.D. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation, a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 1999, 86:1583-1589.
10. August C., August K., Schroeder S. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod. Pathol. 2004, 17:1119-1128.
11. Edstrom E.E., Xu D., Hoog A. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod. Pathol. 2003, 16:246-255.
12. Kumaki N., Kajiwara H., Kameyama K. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr. Pathol. 2002, 13:149-156.
13. Slamon D.J., Godolphin W., Jones L.A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
14. Ranzani G.N., Pellegata N.S., Previdere C. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res. 1990, 50:7811-7814.
15. Slamon D.J., Leyland-Jones B., Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med. 2001, 344:783-792.
16. Matsuda R., Takahashi T., Nakamura S. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am. J. Pathol. 1993, 142:339-346.
17. Zhang P.J., Genega E.M., Tomaszewski J.E. The role of Calretinin, Inhibin, Melan-A, BCL-2, and c-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod. Pathol. 2003, 16:591-597.
18. Koch C.A., Gimm O., Vortmeyer A.O. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?. Ann. N.Y. Acad. Sci. 2006, 1073:517-526.
19. Medeiros L., Wolf B., Balogh K. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum. Pathol. 1985, 16:580-589.
20. Roncalli M., Spring D.R., Vandal I.M. Oncoprotein immunoreactivity in human endocrine tumors. J. Pathol. 1991, 163:117-127.
21. Evers B.M., Rady P.L., Tyring S. Amplification of the HER-2/neu protooncogene in human endocrine tumors. Surgery 1992, 112:211-217.
22. Strong V., Kennedy T., Al-Ahmadie H. Prognostic indicators of malignancy in adrenal pheochromocytoma: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008, 143:759-768.
23. Feng C., Li H.Z., Yan W.G. The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery] 2007, 45. (Abstract).
24. Gross D.J., Munter G., Bitan M. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer 2006, 13:535-540.